Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.
$0.75 -0.02 (-2.01%)
As of 03/22/2023 16:00:01 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.